Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
7.54
-0.14 (-1.82%)
At close: Nov 13, 2026, 4:00 PM EST
7.41
-0.13 (-1.72%)
Pre-market: Nov 16, 2026, 8:12 AM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 12, 2026

Summary

TriLink’s mRNA pipeline is expanding, with over 50 GMP customers and commercial potential of up to $50 million+ per program. Improved visibility, portfolio bundling and a reset cost base support growth and margin ambitions.

Dan Arias
Analyst, Stifel

Okay. Welcome back to the 2026 Stifel Healthcare Conference. Back on the life sciences side, happy to have Maravai with us today. We have Raj Asarpota, CFO, and Jimmy Burnworth, VP of Finance and Sales Operations. Guys, thanks very much for spending some time with us here today.

Raj Asarpota
CFO, Maravai LifeSciences

Thank you, Dan. Appreciate it. I am going to go through a few slides here, then we can pick it up with Q&A.

Dan Arias
Analyst, Stifel

Yeah.

Raj Asarpota
CFO, Maravai LifeSciences

We will be presenting forward-looking statements, so keep that in mind. To kick it off, Maravai LifeSciences is a leading provider of critical technologies and products that enable the development and manufacturing of life-changing therapeutics, vaccines, and diagnostics, with a particular focus on both nucleic acid production and biosafety testing through our two marquee franchises or brand names, TriLink and Cygnus. TriLink is our diversified genetic medicine platform with three distinct sub-segments. You have mRNA with CleanCap and ModTail as the two franchise products with robust R&D and clinical pipeline, our CDMO service that provides support from discovery to late-stage clinical development, then specialty chemistry, which consists of oligonucleotide synthesis, oligos, NTPs, and consumables. On the Cygnus side, we have a comprehensive portfolio of host cell protein assays, including mass spectrometry and broad-based assays, along with contract services, MockV clearance kits, and custom assays.

Just to point out here, Cygnus HCP kits are used in 31 of 31 commercialized CAR-T and cell and gene therapies. A little bit more of a deeper dive into our two reporting segments, Cygnus and TriLink, both that have very different growth dynamics. Starting with TriLink, like I mentioned, that is our genetic medicine platform, accounting for 65% of revenues. Within TriLink, the three buckets, again, as I mentioned previously, mRNA consists of discovery, that is both research and preclinical, GMP, then commercial. As a percent of revenue, that represents 35%, and the five-year expected growth rate there is in the high single digits and low double digits when you fold in commercial revenues expected in 2028 and 2029. CDMO is our contract manufacturing, representing under 10% of revenue and growing at low double digits.

Specialty chemistry, that is oligo synthesis reagents and consumables, is a little bit over 20%, growing at low single digits. TriLink, again, is the flagship that will carry the long-term high growth opportunity for the company, especially as commercial revenue starts to flow in. Cygnus represents 35% of our revenue, growing at mid-single digits, and is the gold standard, steady-eddy, high-margin cash flow business. Looking at TriLink across every stage of mRNA drug development, notwithstanding the spies like us story in the headlines today, we still think NVIDIA is a good analog. The analogy we like to draw is just as NVIDIA does not build AI models, but supplies the compute that every model runs on, similarly, Maravai does not develop the drug, but we supply differentiated technologies and services that hundreds of mRNA and genetic medicine programs are built on.

Walking from left to right here, as we think about the stages of drug development, on the basic research side, we supply CleanCap, ModTail, NTPs, oligos, enzymes, and this is where we seed the market and spur the start of new programs where pricing is not as critical. We want as many programs here to be seeded as possible. Once you move into preclinical, you get a little bit of a scale-up there. Again, CleanCap, ModTail, and GMP enzyme adoption happens here. As you move into clinical, that is where you get a significant step-up in both volume and price as each phase advances. It is critical to point out here that our target for this year was to onboard 10 new GMP customers, which we exceeded, and we are now at just over 50 GMP customers.

Once you get to the commercial stage, you are now significantly scaling CleanCap, and you are also getting the GMP opportunity with ModTail and GMP enzymes, and we think this is a $5 million to a $50 million per program opportunity per year at peak, and I will provide a little bit more detail on that. As we think about clinical phase advancement, again, as each phase advances, it increases our potential revenue per program. As you look at this visual here, the revenue per program, when you are in the preclinical stage, is pretty low, and we think the estimated chances of a program reaching commercialization when it is preclinical are fairly low. But then as you progress into phase I, 10% of those programs have a chance to get to commercial on market. Phase I and phase I to II is about 12% probability.

Phase II is 15%, and then once a program is in phase III, there is a 58%-60% chance that it hits the market. So, we probably weight all of that to help us frame the opportunity for commercial revenue. We look at five different modalities here, and the formula here is you look at each of these modalities, the number of patients per year that would be enrolled in a program, the number of doses that would be administered, the mRNA per dose, and then the price realization impact per unit to assign a value to each of these programs. As you would expect, a prophylactic vaccine, high patient enrollment similar to a COVID vaccine with low doses per year. Also, the mRNA per dose is low, and because of batch pricing, the value that we assign to such a program is on the lower side.

As you step up to personalized medicine and cancer vaccines, the patients per year is lower than a prophylactic vaccine, but the number of doses are significantly higher, and the mRNA per dose, given that there are multiple doses, represents a medium opportunity based on the price and premium we can command there. Likewise, for an mRNA therapeutic, the doses per year now are pretty high, and the mRNA per dose is even higher than a cancer vaccine, and then the price per unit is the highest in terms of opportunity for the company. Likewise, in in vivo gene editing, high patients enrolled, the mRNA doses is pretty high, and again, we've got opportunity to realize price, giving it a high value. Then ex vivo cell therapy is about a medium based on the number of patients that would be enrolled.

So estimated commercial peak by modality, again, $5 million on the low side for something like a prophylactic vaccine, and up to $50 million+ per program for the rest of the modalities. As we think about the pipeline in terms of where our pipeline is in terms of phase and modality, the current program mix is 40% in phase I, 40% in phase I and II, and phase II or phase III is about 20%. Then as you look to the right, like I mentioned, 50 GMP customers in 2026, average of two to three programs per GMP customer, so that gives you a little bit of context on the shots at goal we have and the diversity of programs. Then majority of our pipeline is for the high-value modalities, so 75% + is in those categories outside of prophylactic vaccines.

I'll just close it out by talking a little bit about programs that are in the clinic today. They, of course, use CleanCap, but programs that enter the clinic now, they also leverage both our ModTail and GMP enzymes, which gives us even more opportunity to carry those GMP products and therefore realize into higher revenue streams. So with that, Dan?

Dan Arias
Analyst, Stifel

Yeah, that's a nice breakdown. I think people have been finding the way in which you've been describing the makeup of the businesses to be super helpful just in terms of trying to understand what has been and what might be going forward. So, thank you for those.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

Maybe just as an overall statement, Raj, to start, 2026 has been a more consistent year for Maravai. Can you just talk about where you think you are with visibility across the industry and in those areas—

Raj Asarpota
CFO, Maravai LifeSciences

Sure

Dan Arias
Analyst, Stifel

—broadly speaking, that we just highlighted there?

Raj Asarpota
CFO, Maravai LifeSciences

Sure. I think I'll comment on the business overall, but then specifically by certain segments. Our visibility now compared to what it was 18 months ago has gotten significantly better. I think the COVID bleed down is kind of behind us, as you strip that noise out, the visibility that we have now with both our GMP customers and on the discovery side is a lot better as programs have continued to advance and our forecasting capability has gotten better. On the discovery side, within quarter, we have enough line of sight based on run rate business, forecasts that are available to the commercial team based on their engagement and dialogue with customers. Likewise, for Cygnus, it's pretty good.

The lumpy part, obviously, with GMP, we have a really good line of sight into the funnel, and based on customer schedules, we're able to make those calls either falling within the quarter or depending on what those commitments are in terms of contractual agreements, it may be a little bit longer, which creates that lumpiness, if you will.

Dan Arias
Analyst, Stifel

Yeah. Okay. GMP is a lumpy business, but the visibility when you compare it to just prior periods where you were trying to figure out how much COVID material you needed—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Dan Arias
Analyst, Stifel

—is better than that, I would assume.

Raj Asarpota
CFO, Maravai LifeSciences

Definitely, especially as you think about the programs that are advancing, the number of our GMP customer base is fairly small. Like I said, we have 50 customers, so we understand them really well, understand what their schedules look like, and you cannot obviously time everything, but generally, it is pretty good visibility.

Dan Arias
Analyst, Stifel

Okay. All right. Let me just go into mRNA a little bit. Just under half of TriLink, I believe, and in the quarter, in 3Q, GMP within that was up 30%, and drug discovery was up 27%, so nice growth in both pieces of that. Drug discovery, you increased the number of customers by 70 in the quarter. Which strikes me as a pretty high number for a 90-day period.

Raj Asarpota
CFO, Maravai LifeSciences

Right.

Dan Arias
Analyst, Stifel

Where are these folks coming from? Then can you just talk to the amount of sort of new activity that's driving those guys through the door versus something that's just different about your capabilities at reaching them maybe with—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Dan Arias
Analyst, Stifel

—a commercial force that you didn't have or wasn't as effective or something?

Raj Asarpota
CFO, Maravai LifeSciences

I think I'll start with the capabilities. I think Maravai used to be known as a CleanCap company, but I think now that's changed with the breadth of the portfolio that we're offering. So when you think about ModTail that's bringing customers in, we have IVT Kits, we have enzymes, we've got the mRNAbuilder. So all those factors along with the sales engagement and the capability that we've built is starting to pan out, pay out, like it's playing out to be attracting new customers in. So that 27% growth is not just a function of market growth, but more of us taking share. That's kind of how it's been playing out. In terms of— Jimmy, any comments on the program advancement?

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah, I'd just say we did a deep dive on the 70 new customers, and it really did drive the acceleration, especially in that basic research world. But when you look at it's really three things. It's new products, it's customers coming to us because of our channel, our web e-commerce, and AI capabilities, I'd say drove over half of those new customer acquisitions. Then as Raj mentioned, because of the better segmentation that we've done with the sales force, our sales team is doing a better job at onboarding those larger customers.

Dan Arias
Analyst, Stifel

Okay. Does that tend to be pretty sticky? I mean, do you get some one and dones in there as they're just sort of trialing, or when you get them in the door as a drug discovery customer, do you feel pretty good about— Obviously there's a probability weighting to all of this throughout the continuum, but do you feel good about them sticking with you?

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

We definitely do. Yeah. It's a long tail of customers, but we certainly have those that proceed.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, keep in mind, I mean, that whole discovery business was declining like 20% last year, and we've seen through the year, I think Q1 was like 7%, went to like 15%, 20%, and then finally in Q3 it was up to 27%. Yeah.

Dan Arias
Analyst, Stifel

Yep. Is there anything about I mean, was that like 70% as a sustainable number? How does that strike you as an idea? I mean, was it just an exceptional quarter and so Q4 is a—

Raj Asarpota
CFO, Maravai LifeSciences

Well, Q2 was a record too. We saw like 67 customers going to 70% +. I don't know if it's going to sustain at that level, but certainly in terms of getting new customers in, we feel pretty good about that.

Dan Arias
Analyst, Stifel

Yeah. So the traction as far as bringing new business in at the earlier stages is good.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

Naturally you have those folks graduating, hopefully, through the process, the clinical development process. We've talked about the size of a pre-clinical order being $100,000. I don't know whether that's representative of the overall mix right now. Would you say that that's true? I'd like to just sort of ask a question about the scale-up that you referenced in there, because obviously the amount of material that you use goes up throughout the process.

Raj Asarpota
CFO, Maravai LifeSciences

Right.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah, I think the way to think about it, at the very early stage, it's tens of thousands of dollars as you're starting a program, then as you get deeper into preclinical, then you get into those six-figure numbers. Then once you reach the clinic, that's where you really see a volume scale-up, and it can be 4x or 5x that preclinical number.

Dan Arias
Analyst, Stifel

Okay, so I've got a $10,000 customer, shows up for the first time, $5,000-$10,000, sees some success, and that becomes a $100,000 preclinical program. The multipliers feel like they should. I mean, is a 4x-5x increase for phase I, is that a reasonable assumption?

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah, it's a real way to think about it.

Raj Asarpota
CFO, Maravai LifeSciences

Right.

Dan Arias
Analyst, Stifel

Obviously it doesn't jump that much for the next set of phases, but still multiples of what we're talking about, so maybe 2x-3x .

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, for sure.

Dan Arias
Analyst, Stifel

You could have a $100,000 program right before the clinical process starts, and by the time you are done, that is a $2 million-$3 million.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah, that is about right.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, correct. Which is what gives that variability once you are into GMP, right? You have these large orders with schedules that are driven by customer program timing, but yes, I mean, that is definitely.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

The other dynamic that we see happening is more and more programs are moving away from infectious disease, or the mix is overall improving to cancer vaccines, mRNA therapeutics, in vivo gene editing. Those are programs that require significantly more product and reagent than an infectious disease, and it can be in the magnitude of 20 x, 100 x more mRNA.

Dan Arias
Analyst, Stifel

Yeah. Can we talk about that a little bit? I mean, the personalized vaccines story got a boost in the middle of the year.

Obviously, Merck- Moderna was sort of a proof of principle there. How much more material would you say a project like that would require versus a vaccine? Then if you look at some of the other types of programs that you've talked about, protein replacement, et cetera, same question there, and then what would be the mix there? I mean, I think you had a slide there, but you kind of—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, I mean, I think, yeah, let's say a vaccine, let's say it's like 50 μg per dose. If you're thinking about a vaccine, that's at least one milligram, and with at least nine doses administered, you can do the math on how much of a multiplier that is. Likewise for a therapeutic, that's like 35.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah, I mean, it's even 15x, 20 x more than a—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

—than a cancer vaccine.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

It's significantly higher in terms of dosage.

Dan Arias
Analyst, Stifel

How are you situated with the personal vaccine developers? I mean, you had a program that you talked about. I think the first time that I remember you talking about it was at the Analyst Day in 2023. It was an unnamed partner.

Is that partnership still going on? Would you say that if we think back to the summer and the Merck- Moderna news, should we be looking for some of your partners?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, the answer is yes. We are still working with that partner. The answer is yes on things that are in the pipeline. We obviously can't comment on customers, but the answer is yes.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

Okay, so I've got the scale-up in the clinical development process. I've got material per dose going up. That seems like for pretty much everything on the non-vaccine side, there's a multiplier there.

Raj Asarpota
CFO, Maravai LifeSciences

Right. Yep.

Dan Arias
Analyst, Stifel

I have just this idea that within the programs, you have multiple shots on goal. I guess the question becomes, do your customers on the GMP side usually start with one program and then move to two or three? Or when you get that business, is it typically across the board?

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

It depends on the customer. On average, I would say it usually starts with one and scales up. But with the larger customers, they certainly have even more than three programs going on at a time.

Dan Arias
Analyst, Stifel

Okay. Okay, so if I am rolling this up right, you have your early stage funnel that is expanding in terms of application and the number of programs, increases on the GMP side naturally as some of those graduate. Within that group, you have the material going up and the trial size, just being a greater number of individuals in it. You also have new products in the mix that I assume are, from a technologies point of view, advantageous. Is there a pricing element to some of that as well?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, I mean, if you think about ModTail, when we launched that about a year ago, started off with 70 customers, went to 125 the following quarter, now we are north of 180.

Dan Arias
Analyst, Stifel

Yeah.

Raj Asarpota
CFO, Maravai LifeSciences

The great thing about how we're taking that to market is combining that with CleanCap, and that bundling opportunity, one, gives us stickiness and there's like a 95% attachment, but also ModTails at a premium, so we get that price pop.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Once that moves into GMP, obviously same thing happens based on what we just went through in terms of modality analysis. It gives you a significant pricing premium.

Dan Arias
Analyst, Stifel

What about price as the size of the program grows and presumably the discount on the material? Is that an offset that's because obviously my point is like there's things like—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, of course. I mean, that elasticity is situational, and as things start to scale, you would expect to see a little bit of negotiating. But that's just, when it comes to that, we'll figure it out. But Jimmy, anything—

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Yeah, no.

Raj Asarpota
CFO, Maravai LifeSciences

—or any contract?

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

We want to make all programs economically viable, so we'll certainly work with customers. I think even as we move into the other modalities, there's opportunity to get a higher price than in a prophylactic vaccine because you're now ordering in small batches and more custom order batches, versus a large one-time, once-a-year—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

—order for—

Dan Arias
Analyst, Stifel

I would imagine the discounting that went on during the COVID vaccine period is about as extreme as you would guess. How anything—

Raj Asarpota
CFO, Maravai LifeSciences

Exactly.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Exactly.

Raj Asarpota
CFO, Maravai LifeSciences

Exactly.

Dan Arias
Analyst, Stifel

Okay. How about the competitive environment? I mean, is there anything that is changed there, either favorably or just in a way that makes you think that the operating environment is more difficult in one corner of the market than another?

Raj Asarpota
CFO, Maravai LifeSciences

I mean, just based on our execution and growth, we are seeing I mean, it is starting to get a little stable now in terms of funding and then our execution. I do not know if anyone that has ModTail right now, and CleanCap certainly through COVID has been established as a gold standard. Of course, you have enzymatic capping. But I think kind of even as you step away from that, the more and more we start getting into design services through mRNA and building better mRNA constructs for customers, providing bespoke approaches to developing more targeted experiments for our customers, I think all of that improves the competitive advantage that we have.

Dan Arias
Analyst, Stifel

Okay. Can you just maybe touch on from a commercial standpoint, and maybe this brings Cygnus into the conversation too, just the way that you are going about reaching customers from an e-commerce standpoint and then just being efficient with how it is that you touch some of these new customers that I imagine are, you know of them in the industry, but they are coming to you for the first time in a lot of ways too. So, how is the commercial organization evolving in order to sort of fit the fact that the market is more than just COVID vaccines these days?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. Jimmy's doing that every day.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

I think the segmentation work that we did a year ago is now really paying off in that the long tail of customers placing small orders are getting great service through our e-commerce platform and our AI mRNAbuilder, seen significant adoption in that. Like I said, it was one of the leading drivers of new customer acquisition. Because that is now supporting this tail, it's given our sales reps a lot more time to sell more than just a product, but also to sell a whole platform of products across mRNA. They're upselling ModTail, they're working with them to make sure that they're designing a better mRNA construct. They're also supporting just overall service capabilities and making sure that it's a great experience to work with us.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Then, I think just one last point there too, given the use of AI across the company, we're getting just so much more better in our sales operations capability, giving them the account planning and tools so that they are even more focused as they approach and engage with these customers.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

Yeah. Maybe to that point, I mean, operationally, gross margins, when I'm thinking about the way that the P&L evolves, that's one thing, but gross margins have also changed quite a bit over the last 12 months. I think you had $65 million of cost restructuring last year. How does that situate you for 2027 when you think about how it is that gross margin. I mean, we're never going back to COVID gross margin. I think we would all agree that that's not happening, but it does feel like there's still an upward trajectory here, particularly given the volume.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

How would you have us think about where gross margin—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah. No, that is exactly it. We have talked a lot about the cost base being reset, such that now every dollar of revenue, more than 70% kind of falls to the bottom line. That holds true, and literally, we can flow in hundreds of millions of dollars without meaningfully changing our operating structure. I think in terms of gross margin, a lot of that benefit that we did from the restructuring last year, we saw 1,600 basis points of improvement year-over-year, and EBITDA has grown like $70 million year-over-year, and cash flow is generating nicely. I think going forward, it is a function of obviously the mix of product. You have very high margins in GMP and discovery, and it is a little bit offset by CDMO, but that is a small part of the business, but continuing to get better.

It is a little bit of a function of product mix and then continuing to get manufacturing efficiencies that will drive gross margin.

Dan Arias
Analyst, Stifel

Is there still room to go on manufacturing efficiency?

Raj Asarpota
CFO, Maravai LifeSciences

I think so, a little bit.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

I think so. The biggest initiative this year is really rolling out AI operationally across the board, and so over 40% of our employees are now weekly active users. We've collected hundreds of use cases and are really doing everything we can to drive adoption there, and we're seeing results from that. We think that in the future, it'll mean fewer incremental headcount needed, and as people leave, a little less backfilling.

Raj Asarpota
CFO, Maravai LifeSciences

We already see that in terms of when people leave, backfills are not needed.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

That's good. I think that's happening a lot of different places. Just maybe a short-term question on gross margins in 4Q. Why the step-down? I mean, you've been pretty substantially above where the 4Q implied gross margin number is. Is there something discrete there that you're kind of thinking about?

Raj Asarpota
CFO, Maravai LifeSciences

I mean, I think this—

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

I think we said on the call we are—

Raj Asarpota
CFO, Maravai LifeSciences

Yeah

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

—being fairly conservative on the Q4 margins, and we want to leave some level of discretion to make sure that we account for mix and other potential risks, but we feel very confident in meeting those.

Dan Arias
Analyst, Stifel

Okay. Maybe just to move it down the P&L, the EBITDA line, what do you think the chances are that you can return to something like 35% or 40% EBITDA margins? I mean, those were at one time, ex-COVID, even before COVID, that was a level that was attainable through a certain level of volume.

Raj Asarpota
CFO, Maravai LifeSciences

Right.

Dan Arias
Analyst, Stifel

You sound encouraged by what you are seeing on volume, so maybe just talk to me about whether that is a realistic goal or not.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, that is personally my objective, is I would love to get back to that 35% range, and that is really going to be a function of our execution on the commercial front, right? As those commercial revenues start to fold in, as we continue to build a robust product pipeline, we continue to leverage price, given, again, like the cost structure that is already set, there is no reason why we couldn't get there.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

Maybe just a last question, thinking about the portfolio M&A, is that something that you see as interesting from here? I mean, are you continuing to look to build out the offerings, or is it kind of about what you have today and pushing that as hard as you can?

Raj Asarpota
CFO, Maravai LifeSciences

Yeah, I would say the priority is to continue with the organic initiatives and growth that we have. Having said that, should there be an opportunity in something that is not dilutive to the business and something that is not just technology versus an actual product or service, we will be opportunistic about that. But really, it is about organic growth at this point.

Dan Arias
Analyst, Stifel

Okay.

Raj Asarpota
CFO, Maravai LifeSciences

Yeah.

Dan Arias
Analyst, Stifel

Okay, gentlemen, I appreciate you spending some time. I know you guys are moving around quite a bit, like everyone else, so thanks for participating.

Raj Asarpota
CFO, Maravai LifeSciences

Thank you, Dan.

Jimmy Burnworth
VP of Finance and Sales Operations, Maravai LifeSciences

Thank you, Dan.

Raj Asarpota
CFO, Maravai LifeSciences

Appreciate it.